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Etidronate disodiumEctonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) was originally reported as a responsible gene
for generalized arterial calciﬁcation in infancy (GACI). Though the prognosis of GACI patients is poor because
ofmyocardial infarction and heart failure in relation tomedial calciﬁcation of the coronary arteries, somepatients
rescued by bisphosphonate treatment have been reported. Recently, ENPP1 is also reported as responsible for
autosomal recessive hypophosphatemic rickets type 2. We show here a boy with homozygous ENPP1mutations
diagnosed as having GACI in early infancy. After the diagnosis, he was treated with etidronate disodium (EHDP)
in combination with antihypertensive drugs. The calciﬁcation of major arteries was diminished and disappeared
by the age of eight months. He also showed mild hypophosphatemia (2.6–3.7 mg/dl) from the age of one year.
After the treatment with EHDP for ﬁve years, he showed genu valgum with hypophosphatemia (2.6 mg/dl).
He was diagnosed as having hypophosphatemic rickets at the age of seven years. The ﬁndings that hyper-
mineralization of the arteries and hypo-mineralization of the bone observed in the same patient are noteworthy.
ENPP1 could be regarded as a controller of the calciﬁcation of the whole body at least in part.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Generalized arterial calciﬁcation of infancy (GACI; OMIM #208000)
is a disorder characterized by medial calciﬁcation of elastic ﬁbers in
major arteries, such as aorta, renal arteries and coronary arteries, lead-
ing to angiostenosis throughout the body. Patients suffered from GACI
show fetal distress, poor sucking and hypertension, and are often fatal
within the ﬁrst 6 months due to myocardial infarction and heart failure
(Rutsch et al., 2001; Cheng et al., 2005).
ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) is
reported as one of the responsible genes for GACI (Rutsch et al., 2001).
ENPP1 has nucleotide pyrophosphohydrolase (NPPH) activity in the
extracellular ﬂuid generating inorganic pyrophosphate (PPi) and nucle-
otide monophosphate from nucleotide triphosphate. Accumulated PPi
inhibits alkaline phosphatase (ALP) activity andmineralization throughf infancy; ENPP1, ectonucleotide
e pyrophosphohydrolase; PPi,
scle cells; ARHR2, autosomal
te disodium.
dren's Medical Center, 2-8-29
. This is an open access article underbinding to hydroxyapatite crystals (Fleisch et al., 1966; Addison et al.,
2007; Anderson et al., 2005). Therefore, loss-of-function mutations of
ENPP1 gene cause lack of PPi and up-regulating ALP activity, leading to
promotion of mineralization in the vascular smooth muscle cells
(VSMCs) (Villa-Bellosta et al., 2011; Zhu et al., 2011).
Recently, loss-of-function mutations of ENPP1 gene were also found
in patients with autosomal recessive hypophosphatemic rickets type 2
(ARHR2; OMIM #613312) by linkage analyses (Lorenz-Depiereux
et al., 2010; Levy-Litan et al., 2010). To date, the mechanisms that
loss-of-function mutations of ENPP1 cause hyper-mineralization in the
extra bone tissues and hypo-mineralization in the bone are still unclear.
Etidronate disodium(ethane 1-hydroxy-1, 1-diphosphonate; EHDP)
is one of the ﬁrst-generation bisphosphonates and its structure resem-
bles that of pyrophosphate. It has been reported that treatment with
EHDP improved the overall survival of patients with GACI by
diminishing arterial calciﬁcation (Otero et al., 2013; Edouard et al.,
2011; Galletti et al., 2011; Rutsch et al., 2008). Because the dose of
EHDP required to inhibit bone resorption is near the one that impairs
mineralization, EHDP could also serve as an inhibitor of mineralization
in the bone and in the extra bone tissues (Fleisch, 2002).
We previously reported a boy who was diagnosed as having GACI
with homozygous ENPP1 gene mutations. He was treated with EHDPthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. X-ray pictures of the knee (a) and the ankle (b) of the patient at the age of seven.
(a) Metaphyseal fraying and ﬂaring of the distal end of the femur (arrow) and
metaphyseal fraying of proximal end of the tibia (arrowhead). (b) Metaphyseal fraying
and ﬂaring in the distal end of the tibia (arrow) and the ﬁbula (arrowhead).
Fig. 2. Biochemical parameters and the treatment regimen of the patient. After diagnosis,
the patient was treated with EHDP and antihypertensive drugs. From infantile period,
serum ALP remains high and serum phosphate remains low compared to age-related
references.
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tion of the arteries was disappeared by the age of eight months
(Numakura et al., 2006). Afterwards he showed genu valgum with
hypophosphatemia (2.7 – 3.7 mg/dl) at the age of ﬁve years and
diagnosed as having hypophosphatemic rickets at the age of seven.
Here we report his clinical course and discuss the role of ENPP1 in the
mineralization in the bone and extra bone tissues.
2. Materials & methods
Written informed consent was obtained from the parents of our
patient, and the study was approved by local ethical review board of
our hospital.
2.1. Biochemical measurements
Serum calcium (Ca), phosphate (Pi), ALP levels were measured by
standard colorimetric methods (SRL, Inc., Japan). Serum FGF23 level
wasmeasured by an ELISA kit (Kainos, Japan) which can only recognize
the intact FGF23 (Yamazaki et al., 2002). Tubular reabsorption of
phosphate (%TRP) was calculated by 100 × {1− (urine Pi/serum Pi) /
(urine Cr/serum Cr)}(%). Maximal tubular reabsorption of phosphate
per GFR (TmP/GFR) was calculated by TRP × serum Pi.
3. Case report
Aboy from the ﬁrst-cousin parentswas born by emergency cesarean
section at 36 weeks gestation because of fetal distress. He showed
systemic edema, hepatomegaly and hypertension up to 120 mmHg of
systolic blood pressure. Calciﬁcation of the major arteries including
aorta, carotid artery, renal artery and pulmonary artery was detected
on whole body computed tomography (CT). He was diagnosed as hav-
ing GACI. DNA analyses from the peripheral blood leukocytes showed
that he had homozygous nonsense mutations of ENPP1 gene
(c.2188C N T, p.R730*) and his parents were heterozygous for the
same mutation. NPPH activity of mutated ENPP1 was 4% compared to
control (Numakura et al., 2006). A blood examination showed normal
Ca (10.0 mg/dl), slightly decreased Pi (4.3 mg/dl), and high ALP levels
(2683 IU/l) at the age of two months, when the treatment with EHDP
at a dose of 18 mg/kg was started. To treat hypertension, antihyperten-
sive drugs (amlodipine, lisinopril hydrate and varsartan) were also
started, and then his systolic blood pressure was maintained below
100 mmHg. The calciﬁcation of the arteries was diminished and disap-
peared on CT scanning by the age of eight months. Because hyperten-
sion was improved, treatment with amlodipine and lisinopril hydrate
was stopped at the age of four years. Treatmentwith EHDPwas stopped
by the age of ﬁve years, when he showed genu valgum of the both legs.
At the age of seven years, X-ray of his knee and ankle showed ﬂaying of
metaphyseal bone (Fig. 1). A routine blood examination showed
normocalcemia (8.8–10.4 mg/dl), hypophosphatemia (2.6–3.7 mg/dl),
and high ALP (2591–3836 IU/l) continuously since he was at the age
of one year (Fig. 2). Based on these examinations, he was diagnosed as
having hypophosphatemic rickets. At the age of ten years, serum Pi,
%TRP and TmP/GFR were 2.8 mg/dl, 90.3% and 2.5 mg/dl, respectively.
No ectopic calciﬁcation was observed including major arteries, kidneys,
joints, and spinal ligaments by the age of ten years, and his systolic
blood pressure was maintained below 120 mmHg with varsartan. At
the age of twelve years, high serum FGF23 level (84 pg/ml) was
observed with low serum Pi level (2.8 mg/dl).
4. Discussion
We reported here a case with GACI subsequently developed
hypophosphatemic rickets. To our knowledge, there are only three
reports about GACI patients similar to our patient (Otero et al., 2013;
Edouard et al., 2011; Rutsch et al., 2008).One can easily question why GACI patients showed hypo-
mineralization in the bone after hyper-mineralization in the extra
bone tissues. The signs of GACI are usually evident in early infancy,
even in prenatal period (Eronen et al., 2001; Crade et al., 1991; Nagar
et al., 2003). On the other hand, hypophosphatemia or rickets in GACI
patients were noted ﬁrst at the age between two and three years
(Edouard et al., 2011; Rutsch et al., 2008). To explain these phenotypic
differences depending on age, we speculate possibilities of the change
in the level of serum phosphate, production of FGF23 and treatment
with EHDP.
Age dependent change in serum phosphate levels might explain the
hyper-mineralization in the arteries observed in GACI patients. A previ-
ous report showed that high phosphorus diet exaggerated aortic calciﬁ-
cation in Enpp1−/− mice by the age of two months. In addition,
calcium content of aorta two months after transplantation from two-
month-old wild type mice to Enpp1−/− littermates was signiﬁcantly
greater than that from wild type to wild type, but far lower than that
from Enpp1−/− to Enpp1−/− (Lomashvili et al., 2014). These data
suggest that high Pi/PPi ratio is responsible for arterial calciﬁcation in
early infancy in mice. Circulating Pi is relatively higher in infancy than
Fig. 3. Schema of the calciﬁcation in the VSMCs and osteoblasts in a physiological condition and in a condition with disrupted ENPP1. In a physiological condition, accumulated PPi could
inhibit hydroxyapatite (HA) crystallization in VSMCs (a), and inorganic phosphate could be generated from PPi by highALP activity and used for theHA crystallization in the bone (b). In a
condition of disrupted ENPP1, reduced production of PPi could lead to increased ALP activity and HA production would be increased in concert with circulating inorganic phosphate in
VSMCs (c), and reduced inorganic phosphate generated form PPi could lead to reduced HA production which causes hypo-mineralization in the bone (d). EHDP could serve as inhibitor
of HA crystals (c, d). NTP; nucleotide triphosphate, NMP; nucleotide monophosphate.
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in cord blood was negatively related to gestational age (Fenton et al.,
2011). Thus, high Pi/PPi ratio in early infancy and in fetal period might
be critical for arterial mineralization. This speculation is supported by
the fact that there are no reports about recurrence of arterial calciﬁca-
tion after cessation of EHDP treatment in GACI patients except for one
case whose arterial stenosis was worsened by calcitriol and phosphate
supplementation (Otero et al., 2013; Rutsch et al., 2008; Numakura
et al., 2006).
Hypophosphatemia and hypo-mineralization of the bone in GACI
patients after infancy might be caused by FGF23 elevation resulted
from progression of arterial calciﬁcation. VSMCs from Enpp1−/−mice
up-regulate the expression of Fgf23 in a calciﬁed environment (Tintut
et al., 2003; Zhu et al., 2013), and those treated with recombinant
Fgf23 reduced calcium deposition vice versa (Zhu et al., 2013). These
data suggest that hypophosphatemia observed in patients with ENPP1
mutation might be a byproduct of FGF23 up-regulation, in a hormonal
manner, whereas VSMCs secret to protect themselves from progression
of calciﬁcation in an autocrine or a paracrine manner. It is well known
that FGF23 causes hypophosphatemia by inhibiting both activation
of vitamin D and reabsorption of phosphate in the kidney. As shown in
ARHR2 patients, ENPP1 gene mutations are related to FGF23 elevation
(Levy-Litan et al., 2010; Saito et al., 2011). In our patient, %TRP was rela-
tively low under the condition of hypophosphatemia, and serum FGF23
level was high compared to those of normal subjects (10–50 pg/ml)
(Yamazaki et al., 2002; Igaki et al., 2011). These biochemical data resem-
bled the condition observed with X-linked hypophosphatemic rickets
whose FGF23 levels are often elevated (Morey et al., 2011). It is still
unclear whether the site of FGF23 production in ARHR2 patients and
GACI patients is same.
Mineralization in the bone might be deteriorated by a long term
EHDP treatment. Previous reports showed that patients who suffered
such as Paget's disease and osteoporosis with long term EHDP treat-
ment developed osteomalacia (Hoppé et al., 2012; Thomas et al.,
1995; Siris et al., 1996). Moreover, a cessation of EHDP treated for a
GACI patient led to improvement of rickets (Otero et al., 2013). It is
known that the dose with which EHDP could inhibit bone resorption
is near to that EHDP could inhibit mineralization by binding to the ma-
trix vesicles necessary for precipitation and crystallization of calcium
phosphate salts (Otero et al., 2013; Russell, 2011). Therefore, treatment
with EHDP could inhibit calciﬁcation both in the arteries and in
the bone.It could be speculated that the arterial calciﬁcation is milder, which
may not be clinically detected, in ARHR2 patients in infancy than that
in GACI patients. The arterial calciﬁcation in ARHR2 patients disappears
naturally with a decrease in serum phosphate level. These phenotypical
variances might be explained by genotype of ENPP1mutation because a
previous report showed that mild phenotype of GACI is in relation with
a speciﬁc genotype, although there was a limitation with a small
number of cohort (Rutsch et al., 2008).
From these viewpoints, we speculated the role of ENPP1 in the
mineralization. While ENPP1 is ubiquitously expressed in the body,
activities of ALP are relatively high in osteoblasts compared to VSMCs
(Gomez et al., 1995). When the expression of ENPP1 is disrupted,
reduced extracellular PPi causes high ALP activities in both osteoblasts
and VSMCs. Inorganic phosphate mainly supplied enterally could be
used as a substrate of hydroxyapatite in the arteries as well as in the
bone. Moreover, high inorganic phosphate in fetal, neonatal and infan-
tile periods promotes calciﬁcation of VSMCs, and physiological decrease
of inorganic phosphate by age might reduce the calciﬁcation in the
arteries and in the bone. These temporal differences in the ratio of
Pi to PPi may contribute to the difference of the mineralization in the
body. Furthermore, EHDP could reduce hydroxyapatite leading to
hypo-mineralization both in the arteries and in the bone (Fig. 3).
Clarifying the mechanisms of arterial calciﬁcation in GACI patients
would lead to prevention of arterial calciﬁcation in CKDpatients.Medial
calciﬁcation of arteries is also related to patients with chronic kidney
disease (CKD) (Chowdhury et al., 2004). Pyrophosphate could inhibit
vascular calciﬁcation despite elevated calcium and phosphate concen-
tration in vitro (Lomashvili et al., 2004), and treatment with pyrophos-
phate inhibits arterial calciﬁcation in uremic rats (O'Neill et al., 2011).
These results support that Pi/PPi ratio is the important regulator of
arterial mineralization in uremic patients as is predicted in patients
with GACI.
In conclusion, we reported here a patient with homozygous ENPP1
mutation who suffered hypophosphatemic rickets subsequent to GACI.
Clarifying the mechanisms of mineralization defect of these patients
could further lead to better understanding of the physiological control
of mineralization by ENPP1 in the bone and the extra bone tissues.Disclosure statement
The authors have nothing to disclose.
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